Effect of a multidisciplinary intervention in the clinical evolution of people with mild cognitive impairment

https://neuroprisma.com/aplicacion-de-una-intervencion-multidisciplinaria-para-modificar-el-curso-clinico-de-pacientes-con-deterioro-cognitivo-leve/

The Alzheimer’s disease (AD) and others dementias represent a public health issue in the near future. Multiple risk factors are associated with neurodegenerative conditions, within there are modifiables and not modifiables ones. The main not modifiable risk factor is the association of AD and dementia with certain genes mutations (APP, PSEN1, PSEN2, APOE). The modifiable risk factors are; educational level (years of education), hearing loss, high blood pressure, obesity, diabetes, smoking, depression, sedentary lifestyle and social isolation. In a prodromal stage of the disease, people course with mild cognitive impairment (MCI), which is a condition where the persons have a decline in their cognitive capacity that do not interfere with the ability to do their daily life activities.

Therefore, we aim to evaluate the impact of a multidisciplinary intervention in the clinical course of people with mild cognitive impairment. The program consists of a nutritional program an constant evaluation, physical activity interventions, individual cognitive training, evaluation and control of vascular risk factors.

Inclusion criteria:

  • Age>40 years
  • Mínimum of Elementary school education
  • Meet the criteria for MCI (NIA-AA & DSM-V)
  • CAIDE Dementia Risk Score of 6 or more
  • Adequate control of cardiovascular and metabolic diseases (if present)

Exclusion criteria:

  • Established dementia diagnosis
  • Incapacity to perform moderate physical activity
  • Cancer
  • Alcoholism
  • Drug abuse
  • Use of benzodiazepines or any medication that depresses CNS
  • Use of anorexigenic substances
  • Inadequate control of diabetes
  • Inadequate control of high blood pressure
  • Established diagnosis of ADHD
  • Sensorial deficit (central or peripheral)
  • Severe impairment of speech
  • Polypharmacy adequation

Elimination criteria:

  • Death before completing the trial
  • Life threatening health issues
  • Not meeting the follow up evaluation
  • Will of the patient to leave the trial

Regresar a Investigación